Research Topics
Genomes and Genes | Anat Ben-ShlomoSummaryAffiliation: Cedars-Sinai Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Cell-specific pituitary gene expression profiles after treatment with leukemia inhibitory factor reveal novel modulators for proopiomelanocortin expressionRula A Abbud
Division of Endocrinology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Endocrinology 145:867-80. 2004..Thus, using GeneChips, C/EBPbeta and GIF have been identified as novel mediators and AHSG/fetuin as an inhibitor of LIF action in corticotropes...
Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitisGil Y Melmed
Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
Clin Gastroenterol Hepatol 6:360-3. 2008..The nonapproved use of human growth hormone (HGH) for anti-aging has been increasing. Theoretical concerns for neoplastic potentiation by HGH have been raised, but not proven clinically...
Pituitary gland: predictors of acromegaly-associated mortalityAnat Ben-Shlomo
Pituitary Center, Division of Endocrinology, Diabetes and Metabolism, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Davis Building, Room 3066, Los Angeles, CA 90048, USA
Nat Rev Endocrinol 6:67-9. 2010..A new study by Sherlock et al. now adds adrenal insufficiency and hydrocortisone replacement dose to the list of independent predictors of acromegaly-associated mortality...- AcromegalyAnat Ben-Shlomo
Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA, 90048, USA
Endocrinol Metab Clin North Am 37:101-22, viii. 2008..Pharmacologic treatments, including long-acting somatostatin analogs, dopamine agonists, and growth hormone receptor antagonists, have assumed more importance in achieving biochemical and symptomatic disease control... - Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapyAnat Ben-Shlomo
Department of Medicine, Pituitary Center, Cedars SinaiMedical Center, Los Angeles, California 90048, USA
J Clin Endocrinol Metab 94:4342-50. 2009..However, there is no direct evidence for this assumption, and moreover, the ligand effect on corticotroph SST2 is not known... - Lineage-specific restraint of pituitary gonadotroph cell adenoma growthVera Chesnokova
Department of Medicine, Pituitary Center, Cedars Sinai Medical Center, Los Angeles, California, United States of America
PLoS ONE 6:e17924. 2011..These results point to lineage-specific pathways restricting uncontrolled murine and human pituitary gonadotroph adenoma cell growth... - Senescence mediates pituitary hypoplasia and restrains pituitary tumor growthVera Chesnokova
Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90048, USA
Cancer Res 67:10564-72. 2007.... - Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretionAnat Ben-Shlomo
Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine, UCLA, Los Angeles, California 90048, USA
J Biol Chem 280:24011-21. 2005..This may explain superior somatostatin-28 potency and provides a rationale for somatostatin ligand design to treat ACTH-secreting pituitary tumors... - Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitorNing Ai Liu
Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Proc Natl Acad Sci U S A 108:8414-9. 2011..The results suggest that use of selective CDK inhibitors could effectively target corticotroph tumor growth and hormone secretion... - Somatostatin agonists for treatment of acromegalyAnat Ben-Shlomo
Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Mol Cell Endocrinol 286:192-8. 2008..Disease control is evaluated by biochemical markers, tumor shrinkage, and disease-symptom improvement balanced against drug-related side effects... - Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activationAnat Ben-Shlomo
Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
Mol Endocrinol 21:2565-78. 2007.... - Molecular mechanisms of pituitary adenoma senescenceVera Chesnokova
Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Front Horm Res 38:7-14. 2010..In this review we highlight an intrinsic predisposition of pituitary tumors to exhibit senescence-associated molecular pathways and show prospective mechanisms underlying the benign nature of these commonly encountered tumors... - Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growthVera Chesnokova
Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Mol Endocrinol 26:2092-103. 2012..Thus, gonadotroph tumor cell proliferation is determined by the interplay between cell-specific FOXL2 with PTTG and Clu... - EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomasHidenori Fukuoka
Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
J Clin Invest 121:4712-21. 2011..These results indicate that inhibiting EGFR signaling may be a novel strategy for treating Cushing disease... - Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cellsAnat Ben-Shlomo
Division of Endocrinology and Metabolism, Cedars Sinai Research Institute, University of California School of Medicine, Los Angeles, California 90048, USA
J Clin Endocrinol Metab 88:858-63. 2003..These observations indicate a role for LIF in loss of autocrine PRL suppression contributing to unrestrained prolactinomas PRL secretion. Moreover, PRL suppression by LIF may be mediated by gp130 and D2R interaction... - p21(Cip1) restrains pituitary tumor growthVera Chesnokova
Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Proc Natl Acad Sci U S A 105:17498-503. 2008..Aneuploid pituitary cell p21 may constrain pituitary tumor growth, thus accounting for the very low incidence of pituitary carcinomas... - Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's diseaseAnat Ben Shlomo
Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
IDrugs 10:885-95. 2007..The efficacy of pasireotide and any potential advantage over current therapies will need to be tested or validated in larger phase III clinical trials... - Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegalyAnat Ben-Shlomo
Cedars-Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
J Clin Endocrinol Metab 88:963-8. 2003 - Constitutive somatostatin receptor activity determines tonic pituitary cell responseAnat Ben-Shlomo
Cedars Sinai Medical Center, 8700 Beverly Boulevard, Academic Affairs, Room 2015, Los Angeles, California 90048, USA
Mol Endocrinol 23:337-48. 2009..Thus, integrated pituitary cell ACTH regulation is determined both by phasic SRIF action, as well as by tonic constitutive SST activity, independently of SRIF... - Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligandSong-Guang Ren
Cedars-Sinai Research Institute, University of California School of Medicine, Los Angeles, California 90048, USA
J Clin Endocrinol Metab 88:5414-21. 2003..The SRIF/DA chimeric molecule, BIM-23A387, represents a novel tool for effective drug treatment of acromegaly and for prolactinomas otherwise resistant to dopaminergic therapy... - Medical progress: AcromegalyShlomo Melmed
Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles 90048, USA
N Engl J Med 355:2558-73. 2006 - The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegalyJohn D Carmichael
Department of Medicine, Research Institute, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
J Clin Endocrinol Metab 94:523-7. 2009..The OGTT is the gold standard for determining control of GH secretion at diagnosis and after surgical treatment, but the usefulness of performing an OGTT in patients treated with medical therapy has not been determined... - Murine pituitary tumor-transforming gene functions as a securin protein in insulin-secreting cellsRun Yu
UCLA School of Medicine, Cedars Sinai Research Institute, Cedars Sinai Medical Center, 8700 Beverly Blvd, Room D3066, Los Angeles, California 90048, USA
J Endocrinol 191:45-53. 2006.... - Lipodystrophy in patients with acromegaly receiving pegvisomantVivien S Bonert
Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine at University of California, Los Angeles, California 90048, USA
J Clin Endocrinol Metab 93:3515-8. 2008..Documented side effects in the initial registration studies included headache, injection-site reactions, flu-like syndrome, and reversible elevation of hepatic enzymes... - Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionShlomo Melmed
Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
Pituitary 13:18-28. 2010..Treatment was well tolerated by all patients. In conclusion, Lan-Autogel was effective in controlling GH and IGF-1 hypersecretion in patients with acromegaly and showed a rapid onset of action... - Current status and future opportunities for controlling acromegalyShlomo Melmed
Division of Endocrinology and Metabolism, Ceder Sinai Medical Center, Los Angeles, CA 90048, USA
Pituitary 5:185-96. 2002..Early studies have reported IGF-I normalization in 48% of lanreotide-treated patients and up to 97% of pegvisomant-treated... - Pituitary senescence: the evolving role of PttgVera Chesnokova
Department of Medicine, Division of Endocrinology and Metabolism, Cedars Sinai Medical Center David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90048, USA
Mol Cell Endocrinol 326:55-9. 2010..These observations point to senescence as a target for effective therapy for both tumor silencing and growth restraint towards development of pituitary malignancy... - Opposing effects of pituitary leukemia inhibitory factor and SOCS-3 on the ACTH axis response to inflammationVera Chesnokova
Cedars Sinai Research Institute University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
Am J Physiol Endocrinol Metab 282:E1110-8. 2002..05). The results indicate that, although LIF induces ACTH, SOCS-3 acts to counterregulate the HPA axis response to inflammation... - Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomasAnthony P Heaney
Department of Medicine, Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA
Nat Med 8:1281-7. 2002..Based on these findings, thiazolidinediones may be an effective therapy for Cushing disease.. - The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretionRobert D Murray
Cedars-Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
J Clin Endocrinol Metab 89:3027-32. 2004..As a consequence of its broader binding profile, SOM230 is likely to find clinical utility in treating tumors resistant to SSTR-2-preferential analogs... - Molecular targets in pituitary tumoursAnthony P Heaney
Cedars-Sinai Research Institute, 8700 Beverly Blvd, Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
Nat Rev Cancer 4:285-95. 2004 - Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligandsGeorge Vlotides
Department of Medicine, Cedars Sinai Medical Center, University of California School of Medicine, Los Angeles, California 90048, USA
Cancer Res 68:6377-86. 2008..EGFR inhibitors could therefore be useful for the control of PRL secretion and tumor load in prolactinomas resistant to dopaminergic treatment, or for those prolactinomas undergoing rare malignant transformation... - In vivo time-lapse imaging delineates the zebrafish pituitary proopiomelanocortin lineage boundary regulated by FGF3 signalNing Ai Liu
Department of Medicine, Cedars Sinai Research Institute, University of California Los Angeles, Los Angeles, California 90048, USA
Dev Biol 319:192-200. 2008.... - Constitutive activity of somatostatin receptor subtypesAnat Ben-Shlomo
Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine atUCLA, Los Angeles, California, USA
Methods Enzymol 484:149-64. 2010..We describe methodical validation for each of the approaches and the use of a sensitive cAMP assay to analyze consequences of changing membrane receptor number in the absence of an added ligand... - Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomesOdelia Cooper
Pituitary Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Horm Cancer 1:80-92. 2010..As SCAs exhibit features consistent with both corticotroph and gonadotroph cytologic origin, we propose a pathologic and clinically distinct classification of SCAs as silent corticogonadotroph adenomas... - Skin manifestations in acromegalyAnat Ben-Shlomo
Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
Clin Dermatol 24:256-9. 2006..Discerning these changes contributes to early diagnosis and treatment of this high-morbidity disorder. Controlling GH and IGF-1 over-secretion alleviates most cutaneous manifestations of acromegaly; however, regression may be incomplete... - Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling moleculesVera Chesnokova
Cedars-Sinai Research Institute, University of California-Los Angeles School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
Endocrinology 143:1571-4. 2002..At the same time, gp130 cytokines stimulate pituitary suppressor of cytokine signaling (SOCS)-3, which represses cytokine signaling and abrogates cytokine-induced corticotroph POMC gene transcription and ACTH secretion... - Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine moleculesAnna Gruszka
Division of Endocrinology, Cedars Sinai Research Institute, University of California School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
Endocrinology 148:6107-14. 2007..The results show that SRIF analogs and SRIF/DA molecules inhibit GH and PRL secretion and suppress PRL but not GH gene expression... - Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetesZhiyong Wang
Department of Medicine, Cedars Sinai Research Institute, University of California School of Medicine, Los Angeles, CA 90048, USA
Proc Natl Acad Sci U S A 100:3428-32. 2003..PTTG-/- beta cells had pleiotropic nuclei, suggesting defects in cell division. The results indicated that securin is indispensable for normal pancreatic beta cell proliferation... - PPAR-gamma receptor ligands: novel therapy for pituitary adenomasAnthony P Heaney
Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
J Clin Invest 111:1381-8. 2003..TZDs are proposed as novel oral medications for managing pituitary tumors... - E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumorsCuiqi Zhou
Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
Mol Endocrinol 23:2000-12. 2009..These results elucidate a mechanism for abundant tumor hPTTG1 expression, whereby Rb inactivation releases E2F1 to induce hPTTG1. This signaling pathway may underlie the requirement of PTTG1 for pituitary tumorigenesis... - Implication of pituitary tropic status on tumor developmentInes Donangelo
Cedars-Sinai Research Institute, UCLA School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
Front Horm Res 35:1-8. 2006..Understanding the mechanisms underlying changes in pituitary plasticity and their relationship to tumor development may contribute to the ability of regulating the development and progression of pituitary tumors... - A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegalyShlomo Melmed
Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
J Clin Endocrinol Metab 90:4405-10. 2005.... - Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesisVera Chesnokova
Cedars Sinai Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
Mol Endocrinol 19:2371-9. 2005..01). Pituitary hypoplasia, associated with suppressed cell proliferation, prevents the high penetrance of pituitary tumors in Rb+/- animals, and is therefore a protective determinant for pituitary tumorigenesis... - Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cellsTami Rubinek
Academic Affairs, Rm 2015, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
Am J Physiol Cell Physiol 293:C1082-92. 2007..The results indicate that Pttg deletion reduces BMSC proliferation, renders cells more sensitive to hypoxia, and enhances senescent features, thus pointing to a role for Pttg in the maintenance and proliferation of BMSCs... - Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretionSong-Guang Ren
Cedars-Sinai Research Institute, University of California, Los Angeles, School of Medicine, Los Angeles, California 90048, USA
J Clin Endocrinol Metab 88:4239-45. 2003.... - Mechanisms for pituitary tumorigenesis: the plastic pituitaryShlomo Melmed
Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
J Clin Invest 112:1603-18. 2003.... - Pituitary somatostatin receptor signalingAnat Ben-Shlomo
Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Trends Endocrinol Metab 21:123-33. 2010..Elucidating pituitary SRIF receptor signaling enables understanding of pituitary hormone secretion and cell growth, and also encourages future therapeutic development for pituitary disorders... - Oct-1 induces pituitary tumor transforming gene expression in endocrine tumorsCuiqi Zhou
Department of Medicine Pathology, David Geffen School of Medicine at UCLA, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Endocr Relat Cancer 15:817-31. 2008..05) respectively. The results show that Oct-1 transactivates hPTTG1, and both proteins are concordantly overexpressed in endocrine tumors, thus offering a mechanism for endocrine tumor hPTTG1 abundance... - Update in pituitary diseaseShlomo Melmed
Cedars Sinai Medical Center David Geffen UCLA School of Medicine, Los Angeles, California 90048, USA
J Clin Endocrinol Metab 93:331-8. 2008..Notably, they open up new vistas for creative scholarship in unraveling the challenges of pituitary medicine... - Heregulin regulates prolactinoma gene expressionGeorge Vlotides
Department of Medicine, Cedars Sinai Medical Center, University of California School of Medicine, Los Angeles, CA, USA
Cancer Res 69:4209-16. 2009..Targeted inhibition of up-regulated p185(c-neu)/ErbB3 activity could be useful for the treatment of aggressive prolactinomas resistant to conventional therapy... - A novel molecular marker of pituitary tumor transforming gene involves in a rat liver regenerationKozo Akino
Department of Medicine, Cedars-Sinai Research Institute UCLA School of Medicine, Los Angeles, California, USA
J Surg Res 129:142-6. 2005.... - Pituitary tumor transforming gene: an updateRun Yu
Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA 90048, USA
Front Horm Res 32:175-85. 2004.... - Treatment of acromegaly: futureInes Donangelo
Cedars-Sinai Research Institute, UCLA David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
Endocrine 28:123-8. 2005..Careful individualization of therapy is important in deciding the ideal treatment approach, and primary medical therapy may be recommended in selected patients... - Pituitary corticotroph ontogeny and regulation in transgenic zebrafishNing-Ai Liu
Department of Medicine, Cedars-Sinai Research Institute, University of California Los Angeles School of Medicine, 90048, USA
Mol Endocrinol 17:959-66. 2003..Transgenic zebrafish with specific POMC-GFP expression in pituitary corticotrophs offers a powerful genetic system for in vivo study of vertebrate corticotroph lineage development... - Pituitary tumor transforming gene overexpression facilitates pituitary tumor developmentInes Donangelo
Department of Medicine, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA
Endocrinology 147:4781-91. 2006.... - Functional role of estrogen in pituitary tumor pathogenesisAnthony P Heaney
Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA
J Clin Invest 109:277-83. 2002.... - Central and peripheral actions of somatostatin on the growth hormone-IGF-I axisRobert D Murray
Department of Medicine, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, California 90048, USA
J Clin Invest 114:349-56. 2004..The results demonstrate that SRIF acts both centrally and peripherally to control the GH-IGF-I axis, providing a mechanistic explanation for SRIF analog action in treating patients with GH-secreting pituitary adenomas... - Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomasRun Yu
Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
J Clin Endocrinol Metab 91:5126-9. 2006.... - Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expressionGregory A Horwitz
Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
Mol Endocrinol 17:600-9. 2003..These results indicate that targeting PTTG1-mediated signaling alters the hormonal phenotype in pituitary cells and disrupted PTTG1 action may be a potential subcellular therapeutic tool for repressing PRL hypersecretion... - Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiencyVivien S Bonert
Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, CA 90048, USA
J Clin Endocrinol Metab 89:3397-401. 2004.... - Pituitary tumour-transforming gene (PTTG) and pituitary senescenceVera Chesnokova
Cedars Sinai Medical Center, David Geffen School of Medicine, Los Angeles, CA 90048, USA
Horm Res 71:82-7. 2009..These results improve our understanding of pituitary syndromes associated with infertility, growth disorders, hypercortisolism or adrenal, thyroid and gonadal failure due to abrogated pituitary function... - Acromegaly pathogenesis and treatmentShlomo Melmed
Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
J Clin Invest 119:3189-202. 2009..Effective control of GH and IGF1 hypersecretion and ablation or stabilization of the pituitary tumor mass lead to improved comorbidities and lowering of mortality rates for this hormonal disorder... - Pathogenesis of pituitary tumorsRun Yu
Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
Prog Brain Res 182:207-27. 2010.... - Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cellsRun Yu
Cedars Sinai Research Institute, Universityof California Los Angeles School of Medicine, 90048, USA
Endocrinology 144:4991-8. 2003..These results demonstrate that PTTG induces aneuploidy in single, live, human cancer cells... - Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretionSong-Guang Ren
Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
Endocrinology 147:3936-42. 2006..Pyridoxine may therefore be appropriate for testing as a relatively safe drug for adjuvant treatment of hormone-secreting pituitary adenomas... - Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenomaVivien S Bonert
Cedars Sinai Medical Center, Los Angeles, CA, USA
Nat Clin Pract Endocrinol Metab 2:408-12; quiz following 412. 2006..DIAGNOSIS: Acromegaly and hyperprolactinemia caused by a mixed-cell adenoma, secreting growth hormone and prolactin. MANAGEMENT: Trans-sphenoidal surgery followed by medical therapy with 20 mg intramuscular octreotide-LAR monthly... - Pituitary tumor-transforming gene: physiology and implications for tumorigenesisGeorge Vlotides
Department of Medicine, Cedars Sinai Medical Center, University of California School of Medicine, Los Angeles, California 90048, USA
Endocr Rev 28:165-86. 2007..Recent knowledge gained from PTTG1-null mouse models and transgenic animals and their potential application to subcellular therapeutic targeting PTTG1 are discussed... - Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic miceRula A Abbud
Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
Mol Endocrinol 19:1383-91. 2005..These results provide evidence for early pituitary plasticity, whereby PTTG overexpression results in a phenotype switch in early pituitary stem cells and promotes differentiated polyhormonal cell focal expansion... - The cell adhesion molecules N-cadherin and neural cell adhesion molecule regulate human growth hormone: a novel mechanism for regulating pituitary hormone secretionTami Rubinek
Institute of Endocrinology, Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel
J Clin Endocrinol Metab 88:3724-30. 2003..05). This study indicates that pituitary cell-cell contact mediated by homophilic interactions between adhesion molecules regulates human GH secretion... - Aryl hydrocarbon receptor interacting protein and pituitary tumorigenesis: another interesting proteinShlomo Melmed
J Clin Endocrinol Metab 92:1617-9. 2007 - Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetesPek Yee Lum
Rosetta Inpharmatics, LLC, Merck and Co, Inc, Seattle, WA 98109, USA
J Neurochem 97:50-62. 2006..We identify core functional modules making up the brain transcriptional network in mice that are coherent for core biological processes associated with metabolic disease traits including obesity and diabetes... - Elevated circulating leukemia inhibitory factor in patients with extensive burnsSadanori Akita
Division of Plastic and Reconstructive Surgery, Department of Developmental and Reconstructive Medicine Nagasaki University, Graduate School of Biomedical and Sciences, Nagasaki, Japan
J Burn Care Res 27:221-5. 2006..30; P < .01) as was the correlation of serum LIF with plasma ACTH (r = .24; P < .01). Serum LIF as well as HPA axis activity markers is a good marker of disease severity and prognosis in patients with extensive burns... - 2004 World Health Organization classification of pituitary tumors: what is new?Shlomo Melmed
Acta Neuropathol 111:78-9. 2006 - Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenomaOdelia Cooper
Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, CA 90048, USA
Nat Clin Pract Endocrinol Metab 4:234-8. 2008..A 40-year-old woman presented with galactorrhea and oligomenorrhea. She had a history of multiple ovarian cysts and pelvic pain... - A critical analysis of clinically available somatostatin analog formulations for therapy of acromegalyRobert D Murray
Department of Endocrinology, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK
J Clin Endocrinol Metab 93:2957-68. 2008..A novel aqueous formulation of lanreotide, lanreotide Autogel (ATG), has recently been approved and is the predominant (and only in the United States) formulation of lanreotide used clinically... - Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithmDavid R Clemmons
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
J Clin Endocrinol Metab 88:4759-67. 2003..Pegvisomant is the most effective drug treatment for acromegaly in normalizing IGF-I and producing a clinical response; it is the preferred agent in patients resistant to or intolerant of somatostatin analogs... - Angiogenesis in endocrine tumorsHelen E Turner
Department of Endocrinology, Churchill Hospital, Oxford OX3 7LJ, United Kingdom
Endocr Rev 24:600-32. 2003..An understanding of the balance of angiogenesis in these vascular tumors and mechanisms of vascular control may assist in therapeutic decisions and allow appropriately targeted treatment... - Acromegaly consensus: the next stepsAndrea Giustina
J Clin Endocrinol Metab 88:1913-4. 2003 - [Pituitary tumorigenesis]Marcello D Bronstein
Departamento de Clinica Medica, Hospital das Clinicas, FMUSP, Sao Paulo, SP
Arq Bras Endocrinol Metabol 49:615-25. 2005..Several molecular mechanisms involved in pituitary tumorigenesis have been unraveled including oncogenes, tumor suppressor genes and growth factors involved in neoplastic development, and will be described in this review... - Supplemental growth hormone in healthy adults: the endocrinologist's responsibilityShlomo Melmed
Nat Clin Pract Endocrinol Metab 2:119. 2006 - The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cellsThomas H Gillingwater
Centre for Neuroscience Research, University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK
Hum Mol Genet 15:625-35. 2006..Targeting Wld(S)-induced gene expression may lead to novel therapies for neurodegeneration induced by trauma or by disease in humans... - Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotrophsNing Ai Liu
Department of Medicine, Cedars Sinai Research Institute, University of California, Los Angeles, California 90048, USA
Mol Endocrinol 20:871-80. 2006.... - Expression and function of pituitary tumour transforming gene for T-lymphocyte activationRostyslav Stoika
Division of Endocrinology, Cedars-Sinai Research Institute UCLA School of Medicine, Los Angeles, CA 90048, USA
Br J Haematol 119:1070-4. 2002..These results showed that PTTG-1 expression follows cell cycling patterns in T lymphocytes, providing a convenient model for studying PTTG functions in normal cells...